论文部分内容阅读
十年来在处理局部弥漫性大细胞(组织细胞)淋巴瘤(DLCL)中治疗方式发生了一些变化。1970年以前对Ⅰ、Ⅱ期病人一般采用放疗,结果不能令人满意,5年存活率为25—59%。腹部病变的予后很差,5年存活率仪20%。主要失败原因在于不正确的临床分期、肿瘤的早期转移及腹部病变的处理不当。作者于1972—1981年收治了75例经剖腹证实的Ⅰ、Ⅱ期DLCL 病人,其中45例为腹外病变并行剖腹分期,30例为腹内病变并行剖腹诊断。病人均按Ann Arbor 分期系统分期,治疗方式取决于疾病的表现。一般地,头颈部和小的周围Ⅰ期病变仅用区域放疗,大多数纵隔区、周围较大的病变或膈肌上Ⅱ期病变用局部放疗加化疗,另外包括开始用化疗继之放疗的治疗方式。化疗为环磷酰胺、阿霉
There have been some changes in the treatment of local diffuse large cell (tissue cell) lymphoma (DLCL) over the past decade. Before 1970, radiotherapy was generally applied to patients with stage I and II. The results were unsatisfactory. The 5-year survival rate was 25-59%. Abdominal lesions were poorly postoperative, with a 5-year survival rate of 20%. The main reasons for failure were improper clinical staging, early metastasis of tumors, and improper handling of abdominal lesions. The authors treated 75 cases of stage I-II DLCL patients confirmed by laparotomy from 1972 to 1981, of which 45 cases were abdominal peritoneal staged in parallel and 30 cases were intra-abdominal lesions with laparotomy. Patients were staged by the Ann Arbor staging system, and treatment was dependent on the performance of the disease. In general, head and neck and small surrounding stage I lesions are treated with only regional radiotherapy. Most mediastinal areas, larger lesions around, or phase II lesions in the diaphragm are treated with local radiotherapy plus chemotherapy. In addition, treatment with chemotherapy followed by radiotherapy is included. the way. Chemotherapy for cyclophosphamide